Markets:

Overview

News

Currencies

International

Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.1776 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast

April 19, 2023

From Sangamo Therapeutics, Inc.

Via Business Wire

This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March? ↗

April 19, 2023

A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating...

Via Benzinga

7 Sorry Pharma Stocks to Sell in April Before It’s Too Late ↗

April 16, 2023

You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards.

Via InvestorPlace

Boeing, Spirit AeroSystems And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

April 14, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 15, 2023

On Wednesday, 479 stocks made new 52-week lows.

Via Benzinga

What 4 Analyst Ratings Have To Say About Sangamo Therapeutics ↗

March 03, 2023

Via Benzinga

Earnings Preview For Sangamo Therapeutics ↗

February 21, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

April 10, 2023

Monday's session saw 114 companies set new 52-week lows.

Via Benzinga

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗

March 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

Via InvestorPlace

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo ↗

March 20, 2023

Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.

Via Benzinga

UBS Group, Credit Suisse And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 20, 2023

U.S. stock futures traded mostly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 17, 2023

Via Benzinga

10 Companies That Had Tons of Money in SVB When It Collapsed ↗

March 13, 2023

Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB.

Via InvestorPlace

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗

March 11, 2023

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023 ↗

February 27, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 27, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 24, 2023

On Friday, 135 companies reached new 52-week lows.

Via Benzinga

Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit ↗

February 23, 2023

Via Benzinga

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

From Sangamo Therapeutics, Inc.

Via Business Wire

Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease

February 22, 2023

From Sangamo Therapeutics, Inc.

Via Business Wire

There's a Lot of Upside For Emerging Gene-Editing Companies

February 21, 2023

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

Via MarketBeat

Earnings Scheduled For February 22, 2023 ↗

February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

Via Benzinga

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast

February 21, 2023

From Sangamo Therapeutics, Inc.

Via Business Wire

Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week ↗

February 10, 2023

These cutting-edge biotech companies quickly fell out of favor with investors this week.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Wednesday ↗

December 21, 2022

On Wednesday, 152 stocks made new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

December 28, 2022

On Wednesday, 258 companies hit new 52-week lows.

Via Benzinga

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment ↗

November 29, 2022

Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group,

Via Benzinga

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

November 03, 2022

From Sangamo Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

December 22, 2022

Thursday's session saw 329 companies set new 52-week lows.

Via Benzinga

Earnings Scheduled For November 3, 2022 ↗

November 03, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.